This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages) |
Gabrielle Belz | |
---|---|
Nationality | Australian |
Alma mater | University of Queensland |
Awards | Burnet Prize Gottschalk Medal NHMRC Elizabeth Blackburn Fellowship |
Scientific career | |
Fields | Medicine Immunology Veterinary Science |
Institutions | Walter and Eliza Hall Institute of Medical Research |
Doctoral advisor | Professor Trevor Heath |
Gabrielle T. Belz is an Australian molecular immunologist and viral immunologist. She is a faculty member of the Walter and Eliza Hall Institute of Medical Research, within the Molecular Immunology division. [1] Belz has made important contributions to the understanding of immune system function, especially in relation to the molecular and cellular signalling pathways of immune response to viruses. Her research has focused on understanding the signals that drive the initial development of protective immunity against pathogen infections, such as influenza and herpes viruses. [2] This includes research into how cytotoxic T cells (a type of T lymphocyte that destroys virally infected cells and tumor cells) recognise and remove virally-infected cells from the body following infection. Research into the description of the specific factors and response during infection will contribute towards the long-term development of vaccines for infectious disease, and the development of better treatments for autoimmune diseases.
Belz trained as a veterinarian and completed her undergraduate studies at the University of Queensland graduating with a Bachelor of Veterinary Biology in 1990, then a Bachelor of Veterinary Science with First Class Honours in 1993. She completed a PhD in 1997 at the University of Queensland. Following her PhD, she took up a Postdoctoral Fellowship in viral immunology with Nobel Laureate Professor Peter Doherty at St Jude Children's Research Hospital in Memphis, USA. She returned to Australia to take up a position with the Walter and Eliza Hall Institute of Medical Research in 2000. In 2010, she received a Doctor of Veterinary Science from the University of Queensland.
Belz was Editor-of-Chief of Immunology and Cell Biology until 2016, and was subsequently a Deputy Editor of the journal for several years. She is currently a Deputy Editor for the Journal of Immunology.
In 2007 Belz was awarded the Burnet Prize (recognising the Australian virologist Sir Macfarlane Burnet) for her research into how dendritic cells and cytotoxic T cells work together to defend the body from viral infections. [3]
In 2008, Belz was awarded the Gottschalk Medal by the Australian Academy of Science for her contribution to a series of pioneering discoveries illuminating how the immune system deals with viruses. [4] The same year, she was awarded with the Viertel Senior Medical Research Fellowship. [5]
In 2012, Belz was awarded the NHMRC Elizabeth Blackburn Fellowships award (recognising the Australian-American biological researcher and Nobel Laureate, Professor Elizabeth Blackburn). In 2018 she was elected Fellow of the Australian Academy of Health and Medical Sciences. [6] She received an Australian Laureate Fellowship in 2024. [7]
A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response.
A dendritic cell (DC) is an antigen-presenting cell of the mammalian immune system. A DC's main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and adaptive immune systems.
A cytotoxic T cell (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CD8+ T-cell or killer T cell) is a T lymphocyte (a type of white blood cell) that kills cancer cells, cells that are infected by intracellular pathogens (such as viruses or bacteria), or cells that are damaged in other ways.
The T helper cells (Th cells), also known as CD4+ cells or CD4-positive cells, are a type of T cell that play an important role in the adaptive immune system. They aid the activity of other immune cells by releasing cytokines. They are considered essential in B cell antibody class switching, breaking cross-tolerance in dendritic cells, in the activation and growth of cytotoxic T cells, and in maximizing bactericidal activity of phagocytes such as macrophages and neutrophils. CD4+ cells are mature Th cells that express the surface protein CD4. Genetic variation in regulatory elements expressed by CD4+ cells determines susceptibility to a broad class of autoimmune diseases.
Cross-presentation is the ability of certain professional antigen-presenting cells (mostly dendritic cells) to take up, process and present extracellular antigens with MHC class I molecules to CD8 T cells (cytotoxic T cells). Cross-priming, the result of this process, describes the stimulation of naive cytotoxic CD8+ T cells into activated cytotoxic CD8+ T cells. This process is necessary for immunity against most tumors and against viruses that infect dendritic cells and sabotage their presentation of virus antigens. Cross presentation is also required for the induction of cytotoxic immunity by vaccination with protein antigens, for example, tumour vaccination.
The innate immune system or nonspecific immune system is one of the two main immunity strategies in vertebrates. The innate immune system is an alternate defense strategy and is the dominant immune system response found in plants, fungi, prokaryotes, and invertebrates.
Plasmacytoid dendritic cells (pDCs) are a rare type of immune cell that are known to secrete large quantities of type 1 interferon (IFNs) in response to a viral infection. They circulate in the blood and are found in peripheral lymphoid organs. They develop from bone marrow hematopoietic stem cells and constitute < 0.4% of peripheral blood mononuclear cells (PBMC). Other than conducting antiviral mechanisms, pDCs are considered to be key in linking the innate and adaptive immune systems. However, pDCs are also responsible for participating in and exacerbating certain autoimmune diseases like lupus. pDCs that undergo malignant transformation cause a rare hematologic disorder, blastic plasmacytoid dendritic cell neoplasm.
The type III interferon group is a group of anti-viral cytokines, that consists of four IFN-λ (lambda) molecules called IFN-λ1, IFN-λ2, IFN-λ3, and IFN-λ4. They were discovered in 2003. Their function is similar to that of type I interferons, but is less intense and serves mostly as a first-line defense against viruses in the epithelium.
T helper 17 cells (Th17) are a subset of pro-inflammatory T helper cells defined by their production of interleukin 17 (IL-17). They are related to T regulatory cells and the signals that cause Th17s to actually inhibit Treg differentiation. However, Th17s are developmentally distinct from Th1 and Th2 lineages. Th17 cells play an important role in maintaining mucosal barriers and contributing to pathogen clearance at mucosal surfaces; such protective and non-pathogenic Th17 cells have been termed as Treg17 cells.
Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. LAG3, which was discovered in 1990 and was designated CD223 after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, is a cell surface molecule with diverse biological effects on T cell function but overall has an immune inhibitory effect. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.
Thymic stromal lymphopoietin (TSLP) is an interleukin (IL)-2-like cytokine, alarmin, and growth factor involved in numerous physiological and pathological processes, primarily those of the immune system. It shares a common ancestor with IL-7.
Sérgio A. Lira, is a Brazilian-born American immunologist who pioneered the use of genetic approaches to study the function of chemokines. His early studies were the first to show that chemokines played a major role on leukocyte trafficking to the brain, the lung and the thymus.
Chemorepulsion is the directional movement of a cell away from a substance. Of the two directional varieties of chemotaxis, chemoattraction has been studied to a much greater extent. Only recently have the key components of the chemorepulsive pathway been elucidated. The exact mechanism is still being investigated, and its constituents are currently being explored as likely candidates for immunotherapies.
Innate lymphoid cells (ILCs) are the most recently discovered family of innate immune cells, derived from common lymphoid progenitors (CLPs). In response to pathogenic tissue damage, ILCs contribute to immunity via the secretion of signalling molecules, and the regulation of both innate and adaptive immune cells. ILCs are primarily tissue resident cells, found in both lymphoid, and non- lymphoid tissues, and rarely in the blood. They are particularly abundant at mucosal surfaces, playing a key role in mucosal immunity and homeostasis. Characteristics allowing their differentiation from other immune cells include the regular lymphoid morphology, absence of rearranged antigen receptors found on T cells and B cells, and phenotypic markers usually present on myeloid or dendritic cells.
ILC2 cells, or type 2 innate lymphoid cells are a type of innate lymphoid cell. Not to be confused with the ILC. They are derived from common lymphoid progenitor and belong to the lymphoid lineage. These cells lack antigen specific B or T cell receptor because of the lack of recombination activating gene. ILC2s produce type 2 cytokines and are involved in responses to helminths, allergens, some viruses, such as influenza virus and cancer.
Weiping Zou is the Charles B. de Nancrede Professor of Pathology, Immunology, Biology, and Surgery at the University of Michigan. He is a scientist noted for his work regarding understanding the nature of human tumor immune responses and developing mechanism-informed combination therapies for cancer. He has developed an international reputation in human tumor immunosuppressive mechanisms in the tumor microenvironment.
Franca Ronchese is an Italian-New Zealand immunologist. She currently leads the immune cell biology programme at the Malaghan Institute of Medical Research in Wellington, New Zealand and is a research professor at Victoria University of Wellington.
Laura K. Mackay is an Australian immunologist and Professor of Immunology at the University of Melbourne. Mackay is the Theme Leader in Immunology and Laboratory Head at the Peter Doherty Institute for Infection and Immunity. In 2022, she was the youngest Fellow elected to the Australian Academy of Health and Medical Sciences.
Elina Zúñiga is an Argentinian Immunologist and Professor of Molecular Biology in the Division of Biological Sciences at the University of California, San Diego. Zúñiga has made critical discoveries regarding host-virus interactions in both acute and chronic infections. Using lymphocytic choriomeningitis models (LCMV) and murine cytomegalovirus models, her laboratory at UCSD studies host immune adaptations in chronic viral disease and methods of viral suppression of the immune system in order to develop novel methods and identify novel targets of anti-viral defence. In 2018, Zúñiga was chosen by the American Association of Immunologists to give the international Vanguard Lecture. Zúñiga is also co-founder of the Global Immunotalks series which she and Carla Rothlin started in 2020 as a means to make cutting-edge immunology research freely available and easily accessible to a global audience.
Daniela M. Ferreira is a Brazilian British immunologist. She is a specialist in bacterial infection, respiratory co-infection, mucosal immunology and vaccine responses. She is currently Professor of Respiratory Infection and Vaccinology at the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and the Director of the Liverpool Vaccine Group at the Liverpool School of Tropical Medicine. She leads a team of scientists studying protective immune responses against pneumococcus and other respiratory pathogens such as SARS-CoV2. Her team has established a novel method of inducing pneumococcal carriage in human volunteers. They use this model to: